Examkin

Soru

Zorluk: ZorHematology and Oncology

A 23-year-old man comes to the office to evaluate a progressively enlarging lump on the right side of his neck that he first noticed 6 weeks ago. He also reports drenching night sweats and a 6-kg (13-lb) unintentional weight loss over the past 2 months. His temperature is 37.8°C (100.0°F), blood pressure is 118/76 mm Hg, pulse is 84/min, and respirations are 14/min. Physical examination reveals a 4.5-cm, firm, non-tender, rubbery lymph node in the right supraclavicular region. There is no other cervical, axillary, or inguinal lymphadenopathy. The liver and spleen are not palpable. Complete blood count and comprehensive metabolic panel are within normal limits. Arrange the following steps in the most appropriate chronological order for the evaluation and initial management of this patient's condition.

  1. 1Perform an excisional lymph node biopsy of the supraclavicular mass.
  2. 2Obtain a whole-body positron emission tomography-computed tomography (PET-CT) scan.
  3. 3Assess baseline cardiopulmonary function via echocardiography and pulmonary function testing.
  4. 4Initiate definitive multiagent systemic chemotherapy.

Cevap

The correct sequential order is: 1) Perform an excisional lymph node biopsy, 2) Obtain a whole-body PET-CT scan, 3) Assess baseline cardiopulmonary function, and 4) Initiate definitive multiagent systemic chemotherapy.
The evaluation of a patient presenting with high clinical suspicion for lymphoma follows a strict, sequential clinical pathway to ensure accurate diagnosis, appropriate staging, and patient safety. The absolute first requirement is obtaining a definitive histologic diagnosis through an excisional lymph node biopsy, as fine-needle aspiration disrupts the nodal architecture necessary for precise subtyping. Once the exact subtype (e.g., Hodgkin lymphoma) is known, the disease must be staged. A whole-body PET-CT scan is the standard imaging modality used to evaluate for additional nodal basins and extranodal involvement. The resulting stage dictates the specific chemotherapy regimen (such as ABVD). Because these regimens often include highly toxic agents like doxorubicin (cardiotoxic) and bleomycin (pulmonary toxic), baseline organ function must be formally assessed via echocardiography and pulmonary function testing. Finally, after diagnosis, staging, and safety parameters are fully secured, multiagent systemic chemotherapy can be safely initiated.

Adım Adım Çözüm

1
Establish a definitive histologic diagnosis.
Excisional lymph node biopsy confirms the lymphoma subtype.
A tissue diagnosis is an absolute prerequisite before staging or treating any suspected malignancy. Excisional biopsy preserves nodal architecture, which is critical for lymphoma subtyping.
2
Stage the disease clinically.
Whole-body PET-CT scan delineates the extent of nodal and extranodal involvement.
Accurate staging determines the exact chemotherapy regimen needed, the number of cycles, and whether adjunctive radiation therapy will be required.
3
Perform pre-treatment baseline safety evaluation.
Echocardiography and pulmonary function tests establish baseline organ reserve.
Standard regimens like ABVD contain doxorubicin (cardiotoxic) and bleomycin (pulmonary toxic). Baseline function must be documented before these agents can be safely administered.
4
Commence targeted medical therapy.
Multiagent systemic chemotherapy is initiated safely and effectively.
Curative-intent treatment is the final step, proceeding only after diagnosis, staging, and safety assessments are strictly completed.

Anahtar Kavram

The evaluation of suspected lymphoma follows a strict sequence: histologic confirmation via excisional biopsy, followed by clinical staging via PET-CT, followed by pre-treatment organ function testing, and finally initiation of chemotherapy.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Hematology and Oncology

Bu konudan daha fazla soru